简介:背景:Gankyrin是一个含锚蛋白重复序列的原癌蛋白,其高表达参与了多种恶性肿瘤的发生、发展进程。目的:探讨下调gankyrin表达对胃癌细胞增殖能力的影响及其可能机制。方法:以携带gankyrinsiRNA的慢病毒载体转染人胃癌细胞株MKN28,分别采用MTT实验、流式细胞术和蛋白质印迹法检测下调gankyrin表达对MKN28细胞增殖、细胞周期分布及其β-catenin/cyclinD1信号通路的影响。结果:慢病毒载体的转染效率在90%以上,转染gankyrinsiRNA后,MKN28细胞gankyrin蛋白表达显著受抑(P<0.01)。与未转染慢病毒和转染对照病毒的细胞相比,转染gankyrinsiRNA的MKN28细胞体外生长于第3天起显著受抑,细胞周期G1期细胞比率增高,S期细胞比率降低,细胞中的β-catenin和cyclinD1表达水平降低,差异均有统计学意义(P<0.01)。结论:下调胃癌细胞中的gankyrin表达可通过抑制β-catenin/cyclinD1信号通路引起细胞周期G1期阻滞和细胞增殖抑制,gankyrin有望成为胃癌靶向治疗的新靶点。
简介:AIM:Toevaluatetheefficacyofthe14-dmoxifloxacinbasedtripletherapyforthesecond-lineeradicationofHelicobacterpylori(H.pylori)infection.METHODS:Between2011and2013,weconductedaretrospectivereviewofthemedicalrecordsof160patientswhohadexperiencedfailureoftheirfirst-lineprotonpumpinhibitor-basederadicationtherapyandsubsequentlyreceivedthemoxifloxacin-basedtripletherapyasasecond-lineeradicationtreatmentregimen.Thepatientswhoweretreatedwiththemoxifloxacinbasedtripletherapy(oral20mgrabeprazoleb.i.d.,1000mgamoxicillinb.i.d.,and400mgmoxifloxacinq.d.)for7dwereassignedtotheRAM-7group(n=79)whilethosewhotookthemfor14dayswereassignedtoRAM-14group(n=81).Theeradicationratesforbothgroupsweredeterminedbyintentionto-treat(ITT)andper-protocol(PP)analyses.ITTanalysiscomparedthetreatmentgroupsasoriginallyallocatedwhilethePPanalysisincludingonlythosepatientswhohadcompletedthetreatmentasoriginallyallocated.SuccessfuleradicationtherapyforH.pyloriinfectionwasdefinedasthedocumentationofanegative13C-ureabreathtest4wkaftertheendoftheeradicationtreatment.RESULTS:TheoverallITTeradicationratewas76.2%(122/160).ThefinalITTeradicationrateswere70.8%(56/79;95%CI:63.3%-77.1%)intheRAM-7groupand81.4%(66/81;95%CI:74.6%-88.3%)intheRAM-14group(P=0.034).TheoverallPPeradicationratewas84.1%(122/145),andthefinalPPeradicationrateswere77.7%(56/72;95%CI:70.2%-85.3%)intheRAM-7groupand90.4%(66/73;95%CI:82.8%-98.1%)intheRAM-14group(P=0.017).TheH.pylori-eradicationratesintheRAM-14groupweresignificantlyhighercomparedwiththatoftheRAM-7groupaccordingtoboththeITT(P=0.034)andthePPanalyses(P=0.017).Bothgroupsexhibitedgoodtreatmentcompliance(RAM-7/RAM-14group:100%/100%).Theadverseeventrateswere19.4%(14/72)and20.5%(15/73)intheRAM-7andRAM-14groups,respectively(P=0.441).Adverseeventsoccurredin14
简介:AIM:Toinvestigatetheefficacyofneoadjuvantchemoradiotherapy(NACRT)forresectabilityoflocallyadvancedgastriccancer(LAGC).METHODS:BetweenNovember2007andJanuary2014,29patientswithLAGC(clinicallyT3withdistalesophagusinvasion/T4orbulkyregionalnodemetastasis)thatweretreatedwithNACRTfollowedbyD2gastrectomywereincludedinthisstudy.ResectabilitywasevaluatedwithradiologicandendoscopicexamsbeforeandafterNACRT.Usingthreedimensionalconformalradiotherapy,patientsreceived45Gy,withadailydoseof1.8Gy.Theentiretumorextentandtheregionalmetastaticlymphnodeswereincludedinthegrosstumorvolume.PatientspresentingwitharesectabletumorafterNACRTreceivedatotalorsubtotalgastrectomywithD2dissection.ThepathologictumorresponsewasevaluatedusingJapaneseGastricCancerAssociationhistologicevaluationcriteria.PostoperativemorbiditywasevaluatedusingtheNationalCancerInstitute-CommonTerminologyCriteriaforAdverseEventsversion4.0.Overallsurvival(OS)andprogression-freesurvival(PFS)rateswereestimatedusingaKaplan-Meieranalysisandcomparedusingthelog-ranktest.RESULTS:Allpatientswereassessedasunresectablecases.Twenty-fourpatients(24/29;82.8%)showedLAGConpositronemissiontomography-computedtomography(CT)andcontrast-enhancedCT,whereasfourpatients(4/29;13.8%)withvagueinvasionorabutmenttoanadjacentorganunderwentdiagnosticlaparoscopy.Onepatient(1/29;3.4%),initiallyassessedasaresectablecase,underwentan'openandclosure'afterthetumorwasfoundtobeunresectable.Abutmenttoanadjacentorgan(34.5%)wasthemostcommonreasonforNACRT.TheclinicalresponserateonemonthafterNACRTwas44.8%.AfterNACRT,69%(20/29)ofpatientshadaresectabletumor.Ofthe20patientswitharesectabletumor,18patients(62.1%)underwentaD2gastrectomy.TheR0resectionratewas94.4%andtwopatients(2/18;11.1%)showedacompleteresponse.Themedianfollow-updurationwas13.5mo.Theone-yearOSandPFS
简介:瞄准:与ulcerative(UC)在病人的结肠的粘膜检验metalloproteinase-1(MMP-1)和metalloproteinase-1(TIMP-1)的织物禁止者的表示。方法:颠倒抄写聚合酶链反应(RT-PCR),免疫组织化学被用来与UC和控制在病人在mRNA和蛋白质层次学习MMP-1和TIMP-1的表达式。在MMP-1mRNA,TIMP-1mRNA,MMP-1mRNA/TIMP-1mRNA比率和有UC的病人的临床的症状的严厉之间的关系也被分析。结果:MMP-1mRNA和TIMP-1mRNA在的表示溃烂并且煽动了结肠的粘膜在非煽动的结肠的粘膜比那显著地高(P<0.001),但是有不,统计上,在UC病人和正常的非煽动的结肠的粘膜的有效差量控制(P>0.05)。在UC病人的溃烂的结肠的粘膜的MMP-1和TIMP-1的mRNA表达式被80褶层和2.2褶层增加,分别地什么时候与正常控制相比。在煽动的结肠的粘膜,增加分别地是30褶层和1.6褶层。Immunohistochemical分析显示出那在之中溃烂,发炎,并且UC病人的非煽动的结肠的mucosae和正常控制,MMP-1表示的积极的率分别地是87%,87%,40%和35%,并且TIMP-1表示的积极的率分别地是89%,89%,80%和75%。而且,MMP-1mRNA,TIMP-1mRNA和MMP-1mRNA/TIMP-1mRNA比率的表示与临床的症状(P<0.05)的严厉被相关。结论:在结肠的粘膜在UC病人引起细胞外的矩阵(ECM)和溃疡的过多的水解作用的diseased的MMP-1的过多的表示。MMP-1mRNA,TIMP-1mRNA和MMP-1mRNA/TIMP-1mRNA比率能被用作简历标记与UC在病人判定临床的症状的严厉。外长的TIMP-1或MMP-1禁止者治疗是为有UC的病人的新奇治疗。
简介:AIMToinvestigatetherolesandinteractionsofmutThomolog(MTH)-1andhypoxia-induciblefactor(HIF)-1αinhumancolorectalcancer(CRC).METHODS:TheexpressionanddistributionofHIF-1αandMTH-1proteinsweredetectedinhumanCRCtissuesbyimmunohistochemistryandquantitativerealtimepolymerasechainreaction(qRT-PCR).SW480andHT-29cellswereexposedtonormoxiaorhypoxia.ProteinandmRNAlevelsofHIF-1αandMTH-1wereanalyzedbywesternblottingandqRT-PCR,respectively.InordertodeterminetheeffectofHIF-1αontheexpressionofMTH-1andtheamountof8-oxodeoxyguanosinetriphosphate(dGTP)inSW480andHT-29cells,HIF-1αwassilencedwithsmallinterferingRNA(siRNA).GrowthstudieswereconductedoncellswithHIF-1αinhibitionusingaxenografttumormodel.Finally,MTH-1proteinwasdetectedbywesternblottinginvivo.RESULTS:HighMTH-1mRNAexpressionwasdetectedin64.2%ofcases(54/84),andthiswassignificantlycorrelatedwithtumorstage(P=0.023)andsize(P=0.043).HIF-1αproteinexpressionwascorrelatedsignificantlywithMTH-1expression(R=0.640;P〈0.01)inhumanCRCtissues.HypoxicstressinducedmRNAandproteinexpressionofMTH-1inSW480andHT-29cells.InhibitionofHIF-1αbysiRNAdecreasedtheexpressionofMTH-1andledtotheaccumulationof8-oxo-dGTPinSW480andHT-29cells.Intheinvivoxenografttumormodel,expressionofMTH-1wasdecreasedintheHIF-1αsiRNAgroup,andthetumorvolumewasmuchsmallerthanthatinthemocksiRNAgroup.CONCLUSION:MTH-1expressioninCRCcellswasupregulatedviaHIF-1αinresponsetohypoxicstress,emphasizingthecrucialroleofHIF-1α-inducedMTH-1intumorgrowth.
简介:AIM:Toinvestigatetheeffectsofc-mybantisenseRNAoncellproliferationandtheexpressionofc-myb,TGF-β1andα1-Ⅰcollageninculturedhepaticstellatecells(HSC)fromrats.METHODS:Recombinantretroviralvectorofc-mybantisensegene(pDOR-myb)wasconstructed,andthentransfectedintoretroviralpackagecelllinePA317bymeansofDOTAP.ThepseudovirusesproducedfromtheresistantPA317cellswereselectedwithG418toinfectHSCsisolatedfromratlivers.Thecellproliferationwasmeasuredby3-[4,5-Dimethylthiazolzyl]-2,5-diphenyltetrazo-diumbromide(MTT)method.Theexpressionofc-myb,α1-ⅠcollagenandTGF-β1rnRNA,andc-mybproteininHSCswasdetectedwithsemi-quantitivereversetranseription-polymerasechainreaction(RT-PCR)andWestern-blotrespectively.RESULTS:HSCsfromratswereisolatedsuccessfullywiththeviability>98%.InthepDOR-mybinfectedHSCs,thecmybproteinexpression,cellproliferation,andα1-ⅠcollagenandTGF-β1mRNAexpressionwererepressedsignificantlycomparedwiththeircorrespondingcontrolgroups(P<0.01).CONCLUSION:c-mybplaysakeyroleinactivationandproliferationofHSC.c-mybantisenseRNAcaninhibitcellproliferation,α1-ⅠcollagenandTGF-β1mRNAexpression,suggestingthatinhibitionofc-mybgeneexpressionmightbeapotentialwayforthetreatmentofliverfibrosis.
简介:背景:维生素D受体(VDR)属于类固醇激素受体超家族,参与细胞增殖、分化、凋亡以及免疫应答等多种生物学过程,在多种恶性肿瘤中呈低表达。目的:探讨VDR在结直肠癌中的表达及其调控机制。方法:收集2010年2月-2012年12月上海交通大学医学院附属仁济医院收治的结直肠癌患者30例,以免疫组化法检测癌组织和相应癌旁非癌组织标本的VDR表达情况。从基因表达汇编(GEO)数据库中提取224例结直肠癌患者的临床资料,分析其癌组织VDR表达与患者临床病理特征和生存期的关系。采用组蛋白-赖氨酸N-甲基转移酶EZH2-siRNA或5-氮杂胞嘧啶核苷(5-AZA)处理人结肠癌细胞株HCT116和SW620,以实时PCR检测VDR表达水平,以甲基化特异性PCR(MSP)检测VDR启动子区甲基化水平。结果:结直肠癌患者癌组织VDR阳性表达率显著低于癌旁非癌组织(26.7%对70.0%,P〈0.001)。结直肠癌组织VDR表达与肿瘤组织学分期、远处转移、脉管转移、淋巴结转移呈负相关(P〈0.05);VDR高表达者生存期显著长于低表达者(P=0.032)。与转染对照-siRNA相比,HCT116、SW620细胞转染EZH2-siRNA后,EZH2mRNA表达水平和VDR启动子区甲基化水平均显著降低(P〈0.05),VDRmRNA表达水平显著升高(P〈0.05)。5-AZA处理HCT116、SW620细胞后,VDR启动子区甲基化水平较阴性对照组显著降低(P〈0.05),VDRmRNA表达水平显著升高(P〈0.05)。结论:结直肠癌中VDR表达下调且与患者预后呈正相关。VDR在结直肠癌中的转录抑制受组蛋白甲基化和DNA甲基化共同调控。
简介:患儿女,5岁5个月,藏族。因“皮肤黄、眼黄、尿黄10天”于2016年3月3日收住入院。2016年2月20日无明显诱因下家人发现患儿皮肤黄、眼黄,尿色发黄,伴食欲减退,就诊于当地医院,查肝功能ALT713.6U/L,AST687.5U/L,GGT185.8U/L,ALP712.2U/L,ALB39g/L,TBIL99.6μmol/L,DBIL82.0μmol/L,TBA114.7μmol/L;抗HAV阴性;HBsAb阳性;腹部超声示胆囊壁增厚毛糙,腹腔积液。入院后化验:CHE1728U/L;前白蛋白35.5mg/L;尿常规示尿胆红素阳性,尿胆原阴性;PT19.8s,PTA45%;血常规、粪常规、肾功能、血糖、电解质未见异常。抗-HAV、HBV标志物、抗-HCV、抗-HDV、抗-HEV、抗EB病毒抗体、抗风疹病毒抗体、抗CMV抗体、抗单纯疱疹病毒抗体和抗弓形虫抗体均阴性。抗核抗体(ANA,核均质型)为1:320阳性,其余均阴性;血IgG16.8g/L,IgA、IgM、C3、C4均正常;抗ANCA谱阴性。铜蓝蛋白、RF、叶酸、VB12、铁蛋白、甲状腺激素、ESR、CRP、抗HIV、抗梅毒抗体、AFP、CK、CK-MB、CD4+和CD8+淋巴细胞均未见明显异常。给予还原型谷胱甘肽、复方甘草酸苷、丁二磺酸腺苷蛋氨酸、多烯磷脂酰胆碱注射液、熊去氧胆酸胶囊保肝、抗炎、退黄治疗,维生素K1纠正凝血功能,补充白蛋白、呋塞米治疗。在治疗过程中,